THX PharmaFRA:3VG +1.10%30 PB Ratio is 15.26 as of Jun. 25, 2026. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, THX Pharma ranks worse than 91.73% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), THX Pharma's share price is €3.22. THX Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was €0.21. Hence, THX Pharma's PB Ratio of today is 15.26.
The historical rank and industry rank for THX Pharma's PB Ratio or its related term are showing as below:
FRA:3VG'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 16.48
Current: 16.48
During the past 11 years, THX Pharma's highest PB Ratio was 16.48. The lowest was 0.00. And the median was 0.00.
FRA:3VG's PB Ratio is ranked worse than 91.73% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:3VG: 16.48
During the past 3 years, the average Book Value Per Share Growth Rate was -41.20% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of THX Pharma was 57.20% per year. The lowest was -51.80% per year. And the median was -25.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
THX Pharma PB Ratio Related Terms
THX Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for THX Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, THX Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where THX Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
THX Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
THX Pharma (FRA:3VG) has a PB Ratio of 15.26 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #1131 out of 1233 companies in the Biotechnology industry, placing it in the top 91.7%.
Is THX Pharma's PB Ratio too high?
THX Pharma's current PB Ratio is 15.26. The Biotechnology industry median PB Ratio is 2.80. THX Pharma's value of 15.26 is 445% above this industry median. Based on the distribution chart, THX Pharma ranks #1131 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #1131 out of 1233 companies for PB Ratio. This places THX Pharma in the lower half of its industry. The industry median PB Ratio is 2.80. THX Pharma's value of 15.26 is 445% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. THX Pharma's current PB Ratio of 15.26 is 445% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on THX Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THX Pharma's current PB Ratio is 15.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current PB Ratio of 15.26. The current PB Ratio is 15.26 and 445% above the Biotechnology industry median of 2.80. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current PB Ratio is 15.26 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score
Get the complete analysis for FRA:3VG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3VG has been successfully added to your 
